Works matching AU Cheah, Chan Y.

Results: 57
    1
    2
    3
    4
    5

    Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic.

    Published in:
    Internal Medicine Journal, 2020, v. 50, n. 6, p. 667, doi. 10.1111/imj.14859
    By:
    • Di Ciaccio, Pietro;
    • McCaughan, Georgia;
    • Trotman, Judith;
    • Ho, Phoebe Joy;
    • Cheah, Chan Y.;
    • Gangatharan, Shane;
    • Wight, Joel;
    • Ku, Matthew;
    • Quach, Hang;
    • Gasiorowski, Robin;
    • Polizzotto, Mark N.;
    • Prince, Henry Miles;
    • Mulligan, Stephen;
    • Tam, Constantine S.;
    • Gregory, Gareth;
    • Hapgood, Greg;
    • Spencer, Andrew;
    • Dickinson, Michael;
    • Latimer, Maya;
    • Johnston, Anna
    Publication type:
    Article
    6

    Author reply.

    Published in:
    2019
    By:
    • Trotman, Judith;
    • Cheah, Chan Y.;
    • Marlton, Paula;
    • Opat, Stephen
    Publication type:
    Letter to the Editor
    7
    8
    9
    10
    11
    12
    13

    Dose adjusted- EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.

    Published in:
    British Journal of Haematology, 2017, v. 179, n. 3, p. 503, doi. 10.1111/bjh.14226
    By:
    • Chihara, Dai;
    • Westin, Jason R.;
    • Miranda, Roberto N.;
    • Cheah, Chan Y.;
    • Oki, Yasuhiro;
    • Turturro, Francesco;
    • Romaguera, Jorge E.;
    • Neelapu, Sattva S.;
    • Nastoupil, Lorreta J.;
    • Fayad, Luis E.;
    • Rodriguez, M. Alma;
    • Fowler, Nathan H.;
    • Orlowski, Robert Z.;
    • Wang, Michael;
    • Hagemeister, Fredrick B.;
    • Medeiros, L. Jeffrey;
    • Fanale, Michelle A.
    Publication type:
    Article
    14

    Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.

    Published in:
    British Journal of Haematology, 2016, v. 175, n. 5, p. 876, doi. 10.1111/bjh.14325
    By:
    • El ‐ Galaly, Tarec Christoffer;
    • Cheah, Chan Y.;
    • Hutchings, Martin;
    • Mikhaeel, Nabegh George;
    • Savage, Kerry J.;
    • Sehn, Laurie H.;
    • Barrington, Sally;
    • Hansen, Jakob W.;
    • Poulsen, Mette Ø.;
    • Smith, Daniel;
    • Rady, Kirsty;
    • Mylam, Karen J.;
    • Larsen, Thomas S.;
    • Holmberg, Staffan;
    • Juul, Maja B.;
    • Cordua, Sabrina;
    • Clausen, Michael R.;
    • Jensen, Kristina B.;
    • Bøgsted, Martin;
    • Johnsen, Hans E.
    Publication type:
    Article
    15
    16

    Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.

    Published in:
    British Journal of Haematology, 2016, v. 172, n. 1, p. 80, doi. 10.1111/bjh.13796
    By:
    • Chihara, Dai;
    • Cheah, Chan Y.;
    • Westin, Jason R.;
    • Fayad, Luis E.;
    • Rodriguez, Maria A.;
    • Hagemeister, Fredrick B.;
    • Pro, Barbara;
    • McLaughlin, Peter;
    • Younes, Anas;
    • Samaniego, Felipe;
    • Goy, Andre;
    • Cabanillas, Fernando;
    • Kantarjian, Hagop;
    • Kwak, Larry W.;
    • Wang, Michael L.;
    • Romaguera, Jorge E.
    Publication type:
    Article
    17
    18
    19

    P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT.

    Published in:
    2023
    By:
    • Jurczak, Wojciech;
    • Luigi Zinzani, Pier;
    • Eyre, Toby A.;
    • Cheah, Chan Y.;
    • Ujjani, Chaitra S.;
    • Izutsu, Koji;
    • MA, Shuo;
    • Flinn, Ian;
    • Alencar, Alvaro J.;
    • Lewis, David;
    • Patel, Krish;
    • Maddocks, Kami;
    • Wang, Yucai;
    • Munir, Talha;
    • Zelenetz, Andrew D.;
    • Balbas, Minna;
    • Tsai, Donald E.;
    • Wang, Chunxiao;
    • Wang, Michael L.;
    • Shah, Nirav N.
    Publication type:
    Abstract
    20
    21

    An international real‐world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators.

    Published in:
    British Journal of Haematology, 2025, v. 207, n. 1, p. 123, doi. 10.1111/bjh.20115
    By:
    • Tang, Catherine;
    • Downie, Catriona;
    • Sagoo, Mandeep S.;
    • Pringle, Edward;
    • Suleman, Adam;
    • Lewis, Katharine L.;
    • Zhang, Lucy;
    • Quinn, Daire;
    • Poon, L. M.;
    • Hann, William;
    • Cherepanoff, Svetlana;
    • Coyle, Luke;
    • Kassam, Shireen;
    • McKay, Pamela;
    • Cheah, Chan Y.;
    • Prica, Anca;
    • Smith, Jeffery;
    • Hamad, Nada
    Publication type:
    Article
    22
    23
    24
    25

    Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.

    Published in:
    British Journal of Haematology, 2023, v. 201, n. 5, p. 865, doi. 10.1111/bjh.18704
    By:
    • Lim, Kenneth J. C.;
    • Di Ciaccio, Pietro;
    • Polizzotto, Mark N.;
    • Milliken, Sam;
    • Cochrane, Tara;
    • Goh, Zhong;
    • Shaw, Briony;
    • Perry, Evelyn;
    • Gilbertson, Michael;
    • Kermode, William;
    • Cheah, Chan Y.;
    • Latimer, Maya;
    • Hamad, Nada;
    • Ku, Matthew
    Publication type:
    Article
    26
    27
    28
    29
    30

    The utility and limitations of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 1, p. 49, doi. 10.3109/10428194.2014.910656
    By:
    • Cheah, Chan Y.;
    • Hofman, Michael S.;
    • Seymour, John F.;
    • Ritchie, David S.;
    • Dickinson, Michael;
    • Wirth, Andrew;
    • Prince, H. Miles;
    • Wolf, Max;
    • Januszcewicz, Elchanan H.;
    • Carney, Dennis A.;
    • Herbert, Kirsten E.;
    • Harrison, Simon J.;
    • Burbury, Kate L.;
    • Tam, Constantine S.
    Publication type:
    Article
    31
    32
    33
    34

    Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.

    Published in:
    Acta Haematologica, 2025, v. 148, n. 2, p. 180, doi. 10.1159/000539587
    By:
    • Roeker, Lindsey E.;
    • Coombs, Catherine C.;
    • Shah, Nirav N.;
    • Jurczak, Wojciech;
    • Woyach, Jennifer A.;
    • Cheah, Chan Y.;
    • Patel, Krish;
    • Maddocks, Kami;
    • Wang, Yucai;
    • Zinzani, Pier Luigi;
    • Munir, Talha;
    • Koh, Youngil;
    • Thompson, Meghan C.;
    • Muehlenbein, Catherine E.;
    • Wang, Chunxiao;
    • Sizelove, Richard;
    • Abhyankar, Sarang;
    • Hasanabba, Safarulla;
    • Tsai, Donald E.;
    • Eyre, Toby A.
    Publication type:
    Article
    35
    36
    37
    38

    Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.

    Published in:
    American Journal of Hematology, 2016, v. 91, n. 9, p. 894, doi. 10.1002/ajh.24429
    By:
    • Cheah, Chan Y.;
    • Bröckelmann, Paul J.;
    • Chihara, Dai;
    • Moskowitz, Alison J.;
    • Engert, Andreas;
    • Jerkeman, Mats;
    • El-Galaly, Tarec C.;
    • Augustson, Bradley;
    • Vose, Julie;
    • Bartlett, Nancy L.;
    • Villa, Diego;
    • Connors, Joseph M.;
    • Feldman, Tatyana;
    • Pinnix, Chelsea C.;
    • Milgrom, Sarah A.;
    • Dabaja, Bouthaina;
    • Oki, Yasuhiro;
    • Fanale, Michelle A.
    Publication type:
    Article
    39

    Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

    Published in:
    EJHaem, 2024, v. 5, n. 2, p. 325, doi. 10.1002/jha2.870
    By:
    • Shaw, Briony;
    • Chung, Eliza;
    • Wellard, Cameron;
    • Yoo, Edward;
    • Bennett, Rory;
    • Birks, Callum;
    • Johnston, Anna;
    • Cheah, Chan Y;
    • Hamad, Nada;
    • Simpson, Jock;
    • Barraclough, Allison;
    • Ku, Matthew;
    • Viiala, Nicholas;
    • Ratnasingam, Sumita;
    • Armytage, Tasman;
    • Cochrane, Tara;
    • Chong, Geoffrey;
    • Lee, Denise;
    • Manos, Kate;
    • Keane, Colm
    Publication type:
    Article
    40
    41
    42

    Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.

    Published in:
    European Journal of Haematology, 2023, v. 110, n. 4, p. 386, doi. 10.1111/ejh.13915
    By:
    • Nguyen, James;
    • Wellard, Cameron;
    • Chung, Eliza;
    • Cheah, Chan Y.;
    • Dickinson, Michael;
    • Doo, Nicole Wong;
    • Keane, Colm;
    • Talaulikar, Dipti;
    • Berkahn, Leanne;
    • Morgan, Susan;
    • Hamad, Nada;
    • Cochrane, Tara;
    • Johnston, Anna M.;
    • Forsyth, Cecily;
    • Opat, Stephen;
    • Barraclough, Allison;
    • Mutsando, Howard;
    • Ratnasingam, Sumita;
    • Giri, Pratyush;
    • Wood, Erica M.
    Publication type:
    Article
    43
    44

    Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 370, doi. 10.1016/j.clml.2023.01.014
    By:
    • Goh, Zhong;
    • Latimer, Maya;
    • Lewis, Katharine L.;
    • Cheah, Chan Y.;
    • Ciaccio, Pietro Di;
    • Cushion, Tania;
    • Hawkes, Eliza A.;
    • Harrop, Sean;
    • Ku, Matthew;
    • Campbell, Ashlea;
    • Hamad, Nada;
    • Wood, Erica M.;
    • Chung, Eliza;
    • Chen, Pin-Yen;
    • Cochrane, Tara
    Publication type:
    Article
    45

    IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S404, doi. 10.1016/S2152-2650(21)01912-1
    By:
    • Ghosh, Nilanjan;
    • Zinzani, Pier Luigi;
    • Samaniego, Felipe;
    • Jurczak, Wojciech;
    • Derenzini, Enrico;
    • Reeves, James A.;
    • Knopinska-Posluszny, Wanda;
    • Cheah, Chan Y.;
    • Phillips, Tycel;
    • Lech-Maranda, Ewa;
    • Cheson, Bruce;
    • Calmi, Paolo;
    • Grosicki, Sebastian;
    • Leslie, Lori A.;
    • Chavez, Julio C.;
    • Fonseca, Gustavo;
    • Babu, Sunil;
    • Hodson, Daniel J.;
    • Shao, Spencer H.;
    • Burke, John M.
    Publication type:
    Article
    46

    CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S315, doi. 10.1016/S2152-2650(21)01746-8
    By:
    • Coombs, Catherine C.;
    • Pagel, John M.;
    • Shah, Nirav N.;
    • Lamanna, Nicole;
    • Lech-Maranda, Ewa;
    • Eyre, Toby A.;
    • Woyach, Jennifer A.;
    • Wierda, William G;
    • Cheah, Chan Y.;
    • Roeker, Lindsey;
    • Patel, Manish R.;
    • Fakhri, Bita;
    • Barve, Minal A.;
    • Tam, Constantine S.;
    • Lewis, David J.;
    • Gerson, James N.;
    • Alencar, Alvaro;
    • Taylor, Justin;
    • Abdel-Wahab, Omar;
    • Ghia, Paolo
    Publication type:
    Article
    47

    Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01537-8
    By:
    • Ghosh, Nilanjan;
    • Zinzani, Pier Luigi;
    • Samaniego, Felipe;
    • Jurczak, Wojciech;
    • Derenzini, Enrico;
    • Reeves, James A.;
    • Knopinska-Posluszny, Wanda;
    • Cheah, Chan Y.;
    • Phillips, Tycel;
    • Lech-Maranda, Ewa;
    • Cheson, Bruce;
    • Caimi, Paolo;
    • Grosicki, Sebastian;
    • Leslie, Lori A.;
    • Chavez, Julio C.;
    • Fonseca, Gustavo;
    • Babu, Sunil;
    • Hodson, Daniel J.;
    • Shao, Spencer H.;
    • Burke, John M.
    Publication type:
    Article
    48

    Poster: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01392-6
    By:
    • Coombs, Catherine C.;
    • Pagel, John M.;
    • Shah, Nirav N.;
    • Lamanna, Nicole;
    • Lech-Maranda, Ewa;
    • Eyre, Toby A.;
    • Woyach, Jennifer A.;
    • Wierda, William G.;
    • Cheah, Chan Y.;
    • Roeker, Lindsey;
    • Patel, Manish R.;
    • Fakhri, Bita;
    • Barve, Minal A.;
    • Tam, Constantine S.;
    • Lewis, David J.;
    • Gerson, James N.;
    • Alencar, Alvaro;
    • Taylor, Justin;
    • Abdel-Wahab, Omar;
    • Ghia, Paolo
    Publication type:
    Article
    49

    Oral Abstract: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01273-8
    By:
    • Coombs, Catherine C.;
    • Pagel, John M.;
    • Shah, Nirav N.;
    • Lamanna, Nicole;
    • Lech-Maranda, Ewa;
    • Eyre, Toby A.;
    • Woyach, Jennifer A.;
    • Wierda, William G.;
    • Cheah, Chan Y.;
    • Roeker, Lindsey;
    • Patel, Manish R.;
    • Fakhri, Bita;
    • Barve, Minal A.;
    • Tam, Constantine S.;
    • Lewis, David J.;
    • Gerson, James N.;
    • Alencar, Alvaro;
    • Taylor, Justin;
    • Abdel-Wahab, Omar;
    • Ghia, Paolo
    Publication type:
    Article
    50